SCHEMBL2002274

SCHEMBL2002274

CC(=O)NCCOc1ccc2c(c1)c(Cl)cn2S(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.48
LMNA P02545 2/20 0.48
MTNR1A P48039 6/20 0.48
MTNR1B P49286 6/20 0.48
L3MBTL1 Q9Y468 1/20 0.44
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44
HTR1E P28566 1/20 0.44
HTR1F P30939 1/20 0.44
HTR7 P34969 1/20 0.44
DRD3 P35462 1/20 0.44
BCHE P06276 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7017328 0.83 HTR6 (0.63) HTR6MTNR1AMTNR1BHTR1ADRD2
SCHEMBL1997952 0.81 HTR6 (0.61) HTR6MTNR1AMTNR1BL3MBTL1BCHE
SCHEMBL7018452 0.78 MTNR1A (0.69) MTNR1AMTNR1B
SCHEMBL7024537 0.77 HTR6 (0.77) HTR6MTNR1AMTNR1BHTR1ADRD2
SCHEMBL18222500 0.71 HTR6 (0.52) HTR6MTNR1AMTNR1B
SCHEMBL12344906 0.71 HTR6 (0.64) HTR6LMNAHTR1ADRD2HTR1D
SCHEMBL7023756 0.71 HTR6 (0.68) HTR6MTNR1AMTNR1BHTR1ADRD2
SCHEMBL1998285 0.70 HTR6 (0.51) HTR6BCHE
SCHEMBL28649981 0.70 ALDH1A1 (0.67) LMNAMTNR1AMTNR1BL3MBTL1SMN1; SMN2
SCHEMBL1993693 0.70 HTR6 (0.57) HTR6L3MBTL1BCHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960374-B2 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics PROXIMAGEN LIMITED (GB) 2011-06-14 US disclosed
EP-2091953-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (publ) (SE) 2009-08-26 EP disclosed
US-20080176829-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-07-24 US disclosed
WO-2008054288-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (PUBL) (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176829-A1 Compounds HTR6, HTR1B, HTR1A HTR6 1/4885LMNA 1795/4885MTNR1A 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.